Respect the role (and confidentiality) of the EAB at UCSD—and at all NCI-designated cancer centers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Over the years, I have gained extensive experience with academic cancer center External Advisory Boards, including hosting multiple EAB meetings at my own cancer center, chairing the EABs of nine other NCI designated cancer centers, and serving on many others. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
George J. Weiner, MD
Professor of internal medicine-hematology, oncology, and blood & marrow transplantation, Professor of pharmaceutical sciences and experimental therapeutics, CE Block Chair of Cancer Research, Director emeritus, University of Iowa Holden Comprehensive Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone. 
George J. Weiner, MD
Professor of internal medicine-hematology, oncology, and blood & marrow transplantation, Professor of pharmaceutical sciences and experimental therapeutics, CE Block Chair of Cancer Research, Director emeritus, University of Iowa Holden Comprehensive Cancer Center

Login